We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.
- Authors
Chêne, Geneviève; Angelini, Emmanuelle; Cotte, Laurent; Lang, Jean-Marie; Morlat, Philippe; Rancinan, Corinne; May, Thierry; Journot, Valérie; Raffi, François; Jarrousse, Bernard; Grappin, Michèle; Lepeu, Gérard; Molina, Jean-Michel
- Abstract
The role of nucleoside analogues (NAs) in lipodystrophy (LD) syndrome in human immunodeficiency virus (HIV)-infected patients remains controversial. We studied the prevalence of LD in previously untreated patients randomized to receive different NA combinations (in the ALBI-ANRS 070 trial) for 6 months. At month 30 of follow-up, 37 (31%) of 120 patients had >/=1 morphologic change, and 21 (57%) of 37 had isolated peripheral lipoatrophy; corresponding values for the patients who received only NAs throughout follow-up were 20 (30%) of 66 and 14 (67%) of 21, respectively. In multivariate analysis, factors associated with presence of LD at month 30 were initial assignment to the group receiving stavudine and didanosine (odds ratio [OR], 6.7; P=.02), age (OR for being 10 years older, 3.6; P=.002), and HIV RNA level at month 30 (OR, 0.4; P=.007). No difference was observed in cholesterol and glucose levels as a function of any pattern of antiretroviral exposure. Exposure to stavudine and didanosine was associated with LD syndrome (predominantly lipoatrophy).
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Vol 34, Issue 5, p649
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/338811